Key result
The proportion of real-world nonvalvular atrial fibrillation patients meeting eligibility criteria varied significantly among Phase 3 NOAC trials, with 91% eligible for ARISTOTLE, 78% for RE-LY, 61% for ENGAGE, and 50% for ROCKET-AF.
Why the study?
Phase 3 NOAC trials have variable inclusion criteria that differentiate them from each other and from real-world nonvalvular AF patients.
Cross-Sectional (n=2,802)
Real-world nonvalvular atrial fibrillation patients in Turkey show variable eligibility for Phase 3 NOAC trials, with the ARISTOTLE trial criteria being the most representative of this population.
Answers are grounded in this paper and cite their sources.
Variable real-world eligibility for NOAC trials cautions extrapolation; leaves open generalizability questions for ineligible patients.
Introduction: Although the indication of novel oral anticoagulant (NOAC) treatment in atrial fibrillation (AF) is comparatively similar, Phase 3 NOAC trials have variable inclusion criteria that differentiate each other and also from the real-world population. Aim: We aim to investigate the similarity between real-world nonvalvular AF patients and the population of Phase 3 NOAC trials in terms of eligibility. Methods: A total of 2802 patients using rivaroxaban, dabigatran, and apixaban were retrospectively evaluated. All the patients met the exclusion criteria of NOAC Phase 3 trials. These patient population were compared with the population of Phase 3 rivaroxaban (ROCKET-AF), dabigatran (RELY), apixaban (ARISTOTLE), and edoxaban (ENGAGE) trials in terms of inclusion criteria. Furthermore, the patients were stratified on the basis of CHA2-DS2–VASCc is enaogh score. Results: The proportion of population who met the eligible criteria for ARISTOTLE trial (91%) was different from that of RELY (78%), ROCKET-AF (50%), and ENGAGE (61%) trials (P < 0,001). For the population at intermediate risk (CHA2DS2–VASc score ≥1), the proportion which met the inclusion criteria for RE-LY trial (99%) was different from that of ARISTOTLE (91.2%), ROCKET-AF (50%), and ENGAGE trials (61%) (P < 0.001). For the population at high risk (CHA2DS2–VASc score ≥2), the proportion which met the inclusion criteria was as follows: 94% for ARISTOTLE, 83% for RELY, 65% for ENGAGE, and 53% for ROCKET-AF trials (P < 0.001). In this population, 38% of patients using rivaroxaban, 46% of patients using dabigatran, and 12% patients of using apixaban did not meet the inclusion criteria for the ROCKET-AF, RE-LY, and ARISTOTLE trials, respectively. Conclusion: Eligibility of the real-world population for NOAC trials is variable. A considerable number of real-world patients using NOAC do not meet the inclusion criteria of the corresponding drug.
No takes yet. Share an insight, caveat, or question.
Emren et al. (2020) conducted a cross-sectional in Nonvalvular atrial fibrillation (n=2,802). Phase 3 NOAC trial eligibility criteria was evaluated on Proportion of patients meeting eligibility criteria for ARISTOTLE trial compared to RE-LY, ROCKET-AF, and ENGAGE trials (p=<0.001). The proportion of real-world nonvalvular atrial fibrillation patients meeting eligibility criteria varied significantly among Phase 3 NOAC trials, with 91% eligible for ARISTOTLE, 78% for RE-LY, 61% for ENGAGE, and 50% for ROCKET-AF.
Synapse has enriched 10 related papers. Consider them for comparative context: